Patents by Inventor Edward Unsworth

Edward Unsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
    Publication number: 20070004630
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: September 5, 2006
    Publication date: January 4, 2007
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Miller, Edward Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Vasoregulating compounds and methods of their use
    Publication number: 20050261179
    Abstract: Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock. Other specific embodiments are methods for reversing vasoconstriction of blood vessels, by administering to a subject a therapeutically effect amount of an inhibitor of AM(11-22), sufficient to reduce hypertension in the subject. Compounds and pharmaceutical compositions are also provided, as are kits.
    Type: Application
    Filed: October 3, 2003
    Publication date: November 24, 2005
    Applicant: The Government of the United States of America
    Inventors: Frank Cuttitta, Alfredo Martinez, William Stetler-Stevenson, Edward Unsworth, Juan Saavedra
  • Keratinocyte growth factor-2 formulations
    Patent number: 6869927
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: March 22, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Keratinocyte growth factor-2 formulations
    Publication number: 20040063639
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Application
    Filed: October 30, 2003
    Publication date: April 1, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Keratinocyte growth factor-2 formulations
    Patent number: 6653284
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: November 25, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Keratinocyte growth factor-2 formulations
    Publication number: 20020016295
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Application
    Filed: May 14, 2001
    Publication date: February 7, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Keratinocyte growth factor-2 formulations
    Patent number: 6238888
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 29, 2001
    Assignee: Human Genone Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazel Khan